Antiretroviral Regimens and CD4/CD8 Ratio Normalization in HIV-Infected Patients during the Initial Year of Treatment: A Cohort Study

CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study

(2015) Cristina Mussini et al.   Lancet HIV

Switch to raltegravir decreases soluble CD14 in virologically suppressed overweight women: the Women, Integrase and Fat Accumulation Trial

(2014) JE Lake et al.   HIV MEDICINE

Factors Associated With CD8+ T-Cell Activation in HIV-1–Infected Patients on Long-term Antiretroviral Therapy

(2014) Lu Zheng et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Increased Risk of Serious Non-AIDS-Related Events in HIV-Infected Subjects on Antiretroviral Therapy Associated with a Low CD4/CD8 Ratio

(2014) Sergio Serrano-Villar et al.   PLoS One

Clinical, Immunological and Treatment-Related Factors Associated with Normalised CD4+/CD8+ T-Cell Ratio: Effect of Naïve and Memory T-Cell Subsets

(2014) Willard Tinago et al.   PLoS One

Different Plasma Markers of Inflammation Are Influenced by Immune Recovery and cART Composition or Intensification in Treated HIV Infected Individuals

(2014) Marta Massanella et al.   PLoS One

French 2013 guidelines for antiretroviral therapy of HIV-1 infection in adults

(2014) Bruno Hoen et al.   Journal of the International AIDS Society

HIV-Infected Individuals with Low CD4/CD8 Ratio despite Effective Antiretroviral Therapy Exhibit Altered T Cell Subsets, Heightened CD8+ T Cell Activation, and Increased Risk of Non-AIDS Morbidity and Mortality

(2014) Sergio Serrano-Villar et al.   PLoS Pathogens

The CD4/CD8 ratio as a marker T-cell activation, senescence and activation/exhaustion in treated HIV-infected children and young adults

(2013) Talía Sainz et al.   AIDS

The CD4:CD8 ratio is associated with markers of age-associated disease in virally suppressed HIV-infected patients with immunological recovery

(2013) S Serrano-Villar et al.   HIV MEDICINE

Dynamics of CD8 T-Cell Activation After Discontinuation of HIV Treatment Intensification

(2013) Marta Massanella et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Effects of Switching From Efavirenz to Raltegravir on Endothelial Function, Bone Mineral Metabolism, Inflammation, and Renal Function

(2013) Samir K. Gupta et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Dual therapy with etravirine plus raltegravir for virologically suppressed HIV-infected patients: a pilot study

(2013) P. Monteiro et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Lack of correlation between the size of HIV proviral DNA reservoir and the level of immune activation in HIV-infected patients with a sustained undetectable HIV viral load for 10 years

(2013) Isabelle Poizot-Martin et al.   JOURNAL OF CLINICAL VIROLOGY

Decreases in Inflammatory and Coagulation Biomarkers Levels in HIV-Infected Patients Switching from Enfuvirtide to Raltegravir: ANRS 138 Substudy

(2013) Erika F. Silva et al.   JOURNAL OF INFECTIOUS DISEASES

Predictors of CD4:CD8 Ratio Normalization and Its Effect on Health Outcomes in the Era of Combination Antiretroviral Therapy

(2013) Victor Leung et al.   PLoS One

Raltegravir intensification shows differing effects on CD8 and CD4 T cells in HIV-infected HAART-suppressed individuals with poor CD4 T-cell recovery

(2012) Marta Massanella et al.   AIDS

Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir

(2012) Esteban Martínez et al.   AIDS

Chronic immune activation and decreased CD4 cell counts associated with hepatitis C infection in HIV-1 natural viral suppressors

(2012) Mohammad M. Sajadi et al.   AIDS

A pilot study to assess inflammatory biomarker changes when raltegravir is added to a virologically suppressive HAART regimen in HIV-1-infected patients with limited immunological responses

(2012) Kenneth A Lichtenstein et al.   ANTIVIRAL THERAPY

Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study

(2012) Abdel G Babiker et al.   Clinical Trials

T-Cell Subset Distribution in HIV-1–Infected Patients After 12 Years of Treatment-Induced Viremic Suppression

(2012) Frederikke F. Rönsholt et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

The CD4/CD8 ratio in HIV-infected subjects is independently associated with T-cell activation despite long-term viral suppression

(2012) Sergio Serrano-Villar et al.   JOURNAL OF INFECTION

Impact of Weight on Immune Cell Counts among HIV-Infected Persons

(2011) Nancy F. Crum-Cianflone et al.   Clinical and Vaccine Immunology

Factors influencing the normalization of CD4+ T-cell count, percentage and CD4+/CD8+ T-cell ratio in HIV-infected patients on long-term suppressive antiretroviral therapy

(2011) C. Torti et al.   CLINICAL MICROBIOLOGY AND INFECTION

HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects

(2010) Maria J Buzón et al.   NATURE MEDICINE

A large French prospective cohort of HIV-infected patients: the Nadis Cohort

(2009) P Pugliese et al.   HIV MEDICINE

Immune activation and inflammation in HIV-1 infection: causes and consequences

(2007) V Appay et al.   JOURNAL OF PATHOLOGY